Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05351502 | A Study to Assess the Safety and Efficacy of Nitric Oxide Injection Into Unresectable Solid Primary or Metastatic Tumors | PHASE1 | RECRUITING | 38 | — | — | Aug 14, 2022 | Jun 30, 2025 | Aug 16, 2024 | 4 | Israel |
The incidence and characteristics of adverse events (AEs), serious adverse events (SAEs), dose-limiting toxicities (DLTs) and changes in assessed safety parameters. Toxicity will be graded according to NCI CTCAE version 5.0
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | Subjects will receive 25,000 ppm NO |
| Cohort 2 | EXPERIMENTAL | Subjects will receive 50,000 ppm NO |
| Cohort 3 | EXPERIMENTAL | Subjects will receive 100,000 ppm NO |
| RP2D Expansion | EXPERIMENTAL | Subjects will receive the RP2D dose of NO |
| Name | Type | Description |
|---|---|---|
| Nitric Oxide 25,000 ppm | DRUG | Intratumoral injection of 25,000 gNO |
| Nitric Oxide 50,000 ppm | DRUG | Intratumoral injection of 50000 gNO |
| Nitric Oxide 100,000 ppm | DRUG | Intratumoral injection of 100,000 gNO |
| Nitric Oxide selected dose | DRUG | Intratumoral injection of selected does on gNO |
Inclusion Criteria: * Patient (male or female) is at least 18 years of age at the time of signature of the informed consent form. * Patient has an ECOG Performance Status score of 0-3 and with a life expectancy of ≥3 months. * Patient must have a confirmed diagnosis of at least one unresectable cut...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520 / GEH200521 - Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | — | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |